FDA Approves First-of-its-Kind Migraine Treatment

Allergan’s Ubrelvy (ubrogepant) tablets received the FDA’s approval for the immediate treatment of migraine with or without aura, a visual disturbance or sensory phenomenon caused by the condition.

The novel drug, which is not indicated for preventive treatment, is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists the FDA has approved for acute migraine treatment.

The drug “represents an important new option for the acute treatment of migraine,” according to Billy Dunn, acting director of CDER’s Office of Neuroscience, who noted that that approximately 37 million people in the U.S. experience migraines.